
## Mezgebe Berhe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5883086/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels. Annals of Internal Medicine, 2022, 175, 234-243.	3.9	56
2	Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV. Aids, 2021, 35, 1957-1965.	2.2	23
3	Outcomes analysis in patients with extended-spectrum beta-lactamase bacteremia empirically treated with piperacillin/tazobactam versus carbapenems. Baylor University Medical Center Proceedings, 2019, 32, 187-191.	0.5	9
4	Tularemia Presenting as Pulmonary Nodules in an Immunocompromised Patient. Baylor University Medical Center Proceedings, 2017, 30, 175-176.	0.5	4
5	Impact of antimicrobial selection for prophylaxis of left ventricular assist device surgical infections. Journal of Cardiac Surgery, 2021, 36, 3052-3059.	0.7	3
6	The dynamic treatment of SARS-CoV-2 disease. Baylor University Medical Center Proceedings, 2020, 33, 572-579.	0.5	2
7	Risk Factors for Candidemia as Compared with Patients with Negative Blood Cultures Placed on Empiric Micafungin. Open Forum Infectious Diseases, 2017, 4, S79-S79.	0.9	1
8	Evaluating predictors of invasive candidiasis in patients with and without candidemia on micafungin. Baylor University Medical Center Proceedings, 2018, 31, 30-34.	0.5	1
9	<i>Brucella</i> , a bacterium with multiple ways of causing infection. Baylor University Medical Center Proceedings, 2021, 34, 99-101.	0.5	1
10	Effect on SARS-CoV-2 viral load using combination therapy with casirivimab/imdevimab and remdesivir. Baylor University Medical Center Proceedings, 0, , 1-3.	0.5	1
11	2442. Outcomes in ESBL Bacteremia Empirically Treated With Piperacillin/Tazobactam or Carbapenems. Open Forum Infectious Diseases, 2018, 5, S730-S731.	0.9	0
12	2143. Incidence of Infection in Patients Receiving Short vs. Long Duration of Antimicrobial Prophylaxis in Neurosurgery. Open Forum Infectious Diseases, 2018, 5, S631-S631.	0.9	0
13	Effectiveness of casirivimab/imdevimab in an intensive care unit patient with acute respiratory failure due to SARS-CoV-2 infection. Baylor University Medical Center Proceedings, 2022, 35, 1-3.	0.5	0